These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 72873)

  • 1. [Method of determination of total content of plasminogen, plasminogen proactivator, inhibitors of plasminogen activation and antiplasmins in the blood plasma].
    Aslanian NL; Shukhian VM; Barsegian LKh; Ambartsumian KL
    Lab Delo; 1977; (9):530-2. PubMed ID: 72873
    [No Abstract]   [Full Text] [Related]  

  • 2. [Analytical methods of study of the system of fibrinolysis (plasminogen proactivators-activators, plasminogen-plasmin, antiplasmins, antiactivators) (literature review)].
    Guseĭnov ChS; Golovastova GI; Gorelova AM; Cherenkova GM; Mikhailova ND
    Lab Delo; 1976; (5):276-83. PubMed ID: 62085
    [No Abstract]   [Full Text] [Related]  

  • 3. [Determination of the enzyme activity of the fibrinolytic system using fibrinogen conjugated with peroxidase].
    Liaginskiĭ AV; AfanasenkoGA ; Gudkova EV
    Lab Delo; 1991; (11):27-31. PubMed ID: 1722843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proceedings: Distinction of plasma inhibitor of activator-induced clot lysis from antiplasmins.
    Aoki N; Matsuda M; Moroi M; Yoshida N
    Thromb Diath Haemorrh; 1975 Sep; 34(1):350. PubMed ID: 127401
    [No Abstract]   [Full Text] [Related]  

  • 5. On the reliability of plasminogen measurement employing the proactivator-activator converting method.
    Martin M
    Thromb Haemost; 1976 Dec; 36(3):551-65. PubMed ID: 138961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abnormalities of fibrinolysis in essential hypertension.
    Ettenger MM; MacCarthy EP; Glas-Greenwalt P; Clyne DH; Pollak VE
    J Hypertens Suppl; 1984 Dec; 2(3):S175-8. PubMed ID: 6242555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Fibrinolytic system in patients with nephrotic syndrome].
    Andreenko GV; Poliantseva LR; Smirnova TA; Podorol'skaia LV
    Ter Arkh; 1976; 40(2):89-99. PubMed ID: 135367
    [No Abstract]   [Full Text] [Related]  

  • 8. [Thromboelastographic method of determination of plasminogen proactivator, antiactivator, and antiplasmin activity].
    Levin GIa
    Lab Delo; 1975; (11):650-1. PubMed ID: 54484
    [No Abstract]   [Full Text] [Related]  

  • 9. [Plasminogen determination, using a chromogenic tripeptidic substrate (author's transl)].
    Soria J; Soria C; Samama M
    Pathol Biol (Paris); 1976 Dec; 24(10):725-9. PubMed ID: 138119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The determination of the proactivator of the fibrinolytic system with a quantitative caseinolytic method].
    Spöttl F
    Thromb Diath Haemorrh; 1967 Dec; 18(3-4):393-403. PubMed ID: 4232161
    [No Abstract]   [Full Text] [Related]  

  • 11. [Proactivator-activator system in human plasma fibrinolysis: studies on the synthetic fibrinolytic system composed of functionally pure fibrinogen, plasminogen and proactivator, separated from human plasma].
    Okamoto U
    Nihon Seirigaku Zasshi; 1972 Mar; 34(3):147-55. PubMed ID: 4262660
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunochemical distinction between the inhibitors of plasminogen activation and antiplasmin in human plasma.
    Hender U; Collen D
    Thromb Res; 1976 Jun; 8(6):875-9. PubMed ID: 134465
    [No Abstract]   [Full Text] [Related]  

  • 13. Studies on activator formation in human plasma with streptokinase. III. Investigation of activator kinetics in undiluted plasma in terms of urokinase equivalents.
    Martin M
    Thromb Haemost; 1976 Dec; 36(3):566-81. PubMed ID: 138962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Properties of a partially purified preparation of a circulating plasminogen activator.
    Ogston D; Bennett B; Mackie M
    Thromb Res; 1976 Mar; 8(3):275-84. PubMed ID: 131386
    [No Abstract]   [Full Text] [Related]  

  • 15. [Method of simultaneous determination of kallikrein, plasmin and thrombin precursors and inhibitors in human blood plasma].
    Gomazkov OA; Komissarova NV
    Biull Eksp Biol Med; 1976 May; 81(5):632-4. PubMed ID: 132976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Ability of bovine fibrinogen to accept and retain plasminogen proactivator specific for human blood].
    Belitser VA; Varetskaia TV; Tsariuk LA
    Ukr Biokhim Zh; 1976; 48(6):721-6. PubMed ID: 1034991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human fibroblasts produce inhibitor directed against plasminogen activator when treated with glucocorticoids.
    Crutchley DJ; Conanan LB; Maynard JR
    Ann N Y Acad Sci; 1981; 370():609-16. PubMed ID: 6455956
    [No Abstract]   [Full Text] [Related]  

  • 18. A method for the measurement of fibrinolytic activity based on one dimensional diffusion using small glass tubes. II. With special reference to the differences between the use of plasminogen-rich fibrinogen and that of plasminogen-free fibrinogen as the substrates.
    Yasukouchi T; Fujine M; Kohn S; Sakurama S; Morioka T
    Thromb Haemost; 1977 Jun; 37(3):456-63. PubMed ID: 578026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fatty streaks and fibrous plaques in human aorta show increased plasminogen activator activity.
    Smokovitis A; Kokolis N; Alexaki-Tzivanidou E
    Haemostasis; 1988; 18(3):146-53. PubMed ID: 2972593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
    Glas-Greenwalt P; Kant KS; Allen C; Pollak VE
    J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.